These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24378455)

  • 1. Iron and aluminum in Alzheimer's disease.
    Di Lorenzo F; Di Lorenzo B
    Neuro Endocrinol Lett; 2013; 34(6):504-7. PubMed ID: 24378455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation.
    Kruck TP; Fisher EA; McLachlan DR
    Clin Pharmacol Ther; 1990 Oct; 48(4):439-46. PubMed ID: 2225704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical and surgical treatment of neonatal hemochromatosis: single center experience.
    Heffron T; Pillen T; Welch D; Asolati M; Smallwood G; Hagedorn P; Fasola C; Solis D; Rodrigues J; DePaolo J; Spivey J; Martinez E; Henry S; Romero R
    Pediatr Transplant; 2007 Jun; 11(4):374-8. PubMed ID: 17493216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron and Parkinson's disease.
    Di Lorenzo F
    Neuro Endocrinol Lett; 2015; 36(1):24-7. PubMed ID: 25789591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ
    Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
    Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.
    Percy ME; Kruck TP; Pogue AI; Lukiw WJ
    J Inorg Biochem; 2011 Nov; 105(11):1505-12. PubMed ID: 22099160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
    Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY
    Neurobiol Aging; 2013 Feb; 34(2):562-75. PubMed ID: 22717236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminum toxicity due to intravenous injection of boiled methadone.
    Yong RL; Holmes DT; Sreenivasan GM
    N Engl J Med; 2006 Mar; 354(11):1210-1. PubMed ID: 16540630
    [No Abstract]   [Full Text] [Related]  

  • 14. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.
    McLachlan DR; Smith WL; Kruck TP
    Ther Drug Monit; 1993 Dec; 15(6):602-7. PubMed ID: 8122302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB; Shah FT
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of iron chelation therapy with desferrioxamine and deferiprone.
    Cappellini MD; Musallam KM; Taher AT
    Hemoglobin; 2009; 33 Suppl 1():S58-69. PubMed ID: 20001633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desferrioxamine: its use in iron chelation in thalassemia.
    Sharma BK; Choudhury P; Dubey AP
    Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.